Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
Document › Details

G1 Therapeutics, Inc.. (5/11/16). "Press Release: G1 Therapeutics Secures $47 Million Series C Financing". Research Triangle Park, NC.

Organisations Organisation G1 Therapeutics Inc. (Nasdaq: GTHX)
  Organisation 2 Cormorant Asset Management LLC
Product Product  venture capital
Index term Index term G1 Therapeutics–SEVERAL: investment, 201605 financing round Series C $47m led by new investor Cormorant Asset Management

Proceeds will advance lead CDK4/6 inhibitors through early and mid-stage clinical trials, expand pipeline in multiple oncology indications

G1 Therapeutics, Inc., a clinical-stage oncology company, announced today the completion of a $47 million Series C financing led by new investor Cormorant Asset Management. Additional new investors include Aju IB Investment, Cowen Private Investments, Franklin Templeton Investments and Rock Springs Capital. All existing investors participated in the financing: Eshelman Ventures, Hatteras Venture Partners, Lumira Capital, MedImmune Ventures, Mountain Group Capital, RA Capital and Tavistock Life Sciences.

G1 plans to use the proceeds to advance the clinical development of its lead CDK4/6 inhibitors, G1T28 and G1T38, and to expand its pipeline in multiple oncology indications. G1T28 is a potential first-in-class combination therapy that is currently in two proof-of-concept trials in patients with small-cell lung cancer. G1T38 is a potential best-in-class oral drug that will begin clinical development later this month.

"We are encouraged by the enthusiasm of our new and existing investors in the potential of our CDK4/6 inhibitors to be first and best-in-class therapeutics across multiple oncology indications," said Mark Velleca, MD, PhD, Chief Executive Officer of G1 Therapeutics. "We look forward to advancing our lead therapies through early and mid-stage clinical studies, and expanding our pipeline to address significant unmet needs in people with cancer."

"G1 is an emerging leader in the validated CDK4/6 inhibitor space, with two promising drug candidates that address distinct multi-billion dollar markets," added Bihua Chen, Chief Executive Officer of Cormorant Asset Management.

About G1 Therapeutics, Inc.

G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in people with cancer. The company is advancing G1T28, a potential first-in-class drug candidate, and G1T38, a potential best-in-class compound, in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.

Visit for more information.


Mark Velleca, MD, PhD
G1 Therapeutics

Laura Bagby
6 Degrees Communications

Record changed: 2017-07-16


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for G1 Therapeutics Inc. (Nasdaq: GTHX)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top